|
1
|
Unni KK and Inwards CY: Dahlin’s Bone
Tumors, General Aspects and Data on 10,165 Cases. 6th edition.
Lippincott Williams & Wilkins; Philadelphia, PA: pp. 122–168.
2010
|
|
2
|
Ferrari S, Palmerini E, Staals EL, et al:
The treatment of non-metastatic high grade osteosarcoma of the
extremity: review of the Italian Rizzoli experience. Impact on the
future. Cancer Treat Res. 152:275–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gelderblom H, Jinks RC, Sydes M, et al:
Survival after recurrent osteosarcoma: data from 3 European
Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J
Cancer. 47:895–902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zalupski MM, Rankin C, Ryan JR, et al:
Adjuvant therapy of osteosarcoma - A phase II trial: Southwest
Oncology Group study 9139. Cancer. 100:818–825. 2004.PubMed/NCBI
|
|
5
|
Takeshita H, Gebhardt MC, Springfield DS,
Kusuzaki K and Mankin HJ: Experimental models for the study of drug
resistance in osteosarcoma: P-glycoprotein-positive, murine
osteosarcoma cell lines. J Bone Joint Surg Am. 78:366–375.
1996.PubMed/NCBI
|
|
6
|
Hirata M, Kusuzaki K, Takeshita H,
Hashiguchi S, Hirasawa Y and Ashihara T: Drug resistance
modification using pulsing electromagnetic field stimulation for
multidrug resistant mouse osteosarcoma cell line. Anticancer Res.
21:317–320. 2001.PubMed/NCBI
|
|
7
|
Sack H: Radiation therapy and chemotherapy
of primary malignant tumors of the bone. Rontgenblatter.
29:424–429. 1976.(In German).
|
|
8
|
Schwarz R, Bruland O, Cassoni A, Schomberg
P and Bielack S: The role of radiotherapy in osteosarcoma. Cancer
Treat Res. 152:147–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ryu K, Murata H, Koto K, et al: Combined
effects of bisphosphonate and radiation on osteosarcoma cells.
Anticancer Res. 30:2713–2720. 2010.PubMed/NCBI
|
|
10
|
Quiet CA, Weichselbaum RR and Grdina DJ:
Variation in radiation sensitivity during the cell cycle of two
human squamous cell carcinomas. Int J Radiat Oncol Biol Phys.
20:733–738. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tell R, Heiden T, Granath F, Borg AL, Skog
S and Lewensohn R: Comparison between radiation-induced cell cycle
delay in lymphocytes and radiotherapy response in head and neck
cancer. Br J Cancer. 77:643–649. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yacoub A, Miller A, Caron RW, et al:
Radiotherapy-induced signal transduction. Endocr Relat Cancer.
13:S99–S114. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marampon F, Gravina GL, Di Rocco A, et al:
MEK/ERK inhibitor U0126 increases the radiosensitivity of
rhabdomyosarcoma cells in vitro and in vivo by downregulating
growth and DNA repair signals. Mol Cancer Ther. 10:159–168. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsui TA, Sowa Y, Yoshida T, et al:
Sulforaphane enhances TRAIL-induced apoptosis through the induction
of DR5 expression in human osteosarcoma cells. Carcinogenesis.
27:1768–1777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Talalay P, Cho CG and Posner GH:
A major inducer of anticarcinogenic protective enzymes from
broccoli: isolation and elucidation of structure. Proc Natl Acad
Sci USA. 89:2399–2403. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jackson SJT and Singletary KW:
Sulforaphane: a naturally occurring mammary carcinoma mitotic
inhibitor, which disrupts tubulin polymerization. Carcinogenesis.
25:219–227. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gamet-Payrastre L, Li P, Lumeau S, et al:
Sulforaphane, a naturally occurring isothiocyanate, induces cell
cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer
Res. 60:1426–1433. 2000.PubMed/NCBI
|
|
18
|
Fimognari C, Nusse M, Cesari R, Iori R,
Cantelli-Forti G and Hrelia P: Growth inhibition, cell-cycle arrest
and apoptosis in human T-cell leukemia by the isothiocyanate
sulforaphane. Carcinogenesis. 23:581–586. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parnaud G, Li P, Cassar G, et al:
Mechanism of sulforaphane-induced cell cycle arrest and apoptosis
in human colon cancer cells. Nutr Cancer. 48:198–206. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh SV, Herman-Antosiewicz A, Singh AV,
et al: Sulforaphane-induced G2/M phase cell cycle arrest involves
checkpoint kinase 2-mediated phosphorylation of cell division cycle
25C. J Biol Chem. 279:25813–25822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsui TA, Murata H, Sakabe T, et al:
Sulforaphane induces cell cycle arrest and apoptosis in murine
osteosarcoma cells in vitro and inhibits tumor growth in
vivo. Oncol Rep. 18:1263–1268. 2007.PubMed/NCBI
|
|
22
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shankar S, Ganapathy S and Srivastava RK:
Sulforaphane enhances the therapeutic potential of TRAIL in
prostate cancer orthotopic model through regulation of apoptosis,
metastasis, and angiogenesis. Clin Cancer Res. 14:6855–6866. 2008.
View Article : Google Scholar
|
|
24
|
Yu D, Sekine-Suzuki E, Xue L, Fujimori A,
Kubota N and Okayasu R: Chemopreventive agent sulforaphane enhances
radiosensitivity in human tumor cells. Int J Cancer. 125:1205–1211.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kotowski U, Heiduschka G, Brunner M, et
al: Radiosensitization of head and neck cancer cells by the
phytochemical agent sulforaphane. Strahlenther Onkol. 187:575–580.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Asai T, Ueda T, Itoh K, et al:
Establishment and characterization of a murine osteosarcoma cell
line (LM8) with high metastatic potential to the lung. Int J
Cancer. 76:418–422. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim MR, Zhou L, Park BH and Kim JR:
Induction of G2/M arrest and apoptosis by sulforaphane
in human osteosarcoma U2-OS cells. Mol Med Rep. 4:929–934.
2011.PubMed/NCBI
|
|
28
|
Hu R, Hebbar V, Kim BR, et al: In vivo
pharmacokinetics and regulation of gene expression profiles by
isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther.
310:263–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye L, Dinkova-Kostova AT, Wade KL, Zhang
Y, Shapiro TA and Talalay P: Quantitative determination of
dithiocarbamates in human plasma, serum, erythrocytes and urine:
pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin
Chim Acta. 316:43–53. 2002. View Article : Google Scholar
|
|
30
|
Sheplan LJ and Juliano JJ: Use of
radiation therapy for patients with soft-tissue and bone sarcomas.
Cleve Clin J Med. 77:S27–S29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao Y, Jiang W, Li B, et al: Artesunate
enhances radiosensitivity of human non-small cell lung cancer A549
cells via increasing NO production to induce cell cycle arrest at
G2/M phase. Int Immunopharmacol. 11:2039–2046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu J, Liu F, Sun M, Sun Z and Sun S:
Enhancement of radiosensitivity and the potential mechanism on
human esophageal carcinoma cells by tetrandrine. Cancer Biother
Radiopharm. 26:437–442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Forde JC, Maginn EN, McNamara G, et al:
Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells
in vitro. Cancer Biol Ther. 11:421–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
PosthumaDeBoer J, Würdinger T, Graat HCA,
et al: WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC
Cancer. 11:1562011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim IA, Bae SS, Fernandes A, et al:
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt
isoforms increases the radiosensitivity of human carcinoma cell
lines. Cancer Res. 65:7902–7910. 2005.PubMed/NCBI
|
